CLINICAL_TRIALS
trial_result
· 2015-07-15
Clinical Trial Update: Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer [Phase 3]
Summary
Phase 3 trial update assessing Triptorelin (Decapeptyl) 22.5 mg on two biomarkers in advanced prostate cancer, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-07-15